| DURECT Corp. is a biopharmaceutical company, which engages in the research, development, and manufacturing of pharmaceutical products. Its product pipeline consists of multiple investigational drug candidates in clinical development. It offers DUR-928, which focuses on lipid homeostasis, inflammation, and cell survival; POSIMIR, which is an analgesic product intended to deliver bupivacaine to provide pain relief after surgery; and REMOXY ER, which provides investigational extended release pain relief. |
|
